Drugs / Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06744205 | Jan 2025 → May 2026 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06744205 ↗ |
| Modality | Messenger RNA (mRNA) | “messenger ribonucleic acid (mRNA)” NCT06744205 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular injection” NCT06744205 ↗ |